ELITE PHARMACEUTICAL
ELI
ELI was delisted on the 20th of May, 2009.
2 hedge funds and large institutions have $13K invested in ELITE PHARMACEUTICAL in 2020 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
333% more capital invested
Capital invested by funds: $3K → $13K (+$10K)
100% more funds holding
Funds holding: 1 → 2 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
IFP Advisors
Tampa,
Florida
|
+$10K |
Top Sellers
ELI Hedge Fund Activity: Q4 2020 in Review
2 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q4 2020, worth a combined $13K — up 333% from $3K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ELI positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was IFP Advisors, opening a new position worth an estimated $10K.
- 2 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q4 2020, up from 1 in Q3 2020.
- Funds reported $13K of ELITE PHARMACEUTICAL stock for Q4 2020, up 333% quarter-over-quarter.
- 1 fund opened new ELITE PHARMACEUTICAL positions in Q4 2020 and 0 closed out, a net change of +1 holder.
- The largest ELITE PHARMACEUTICAL buyer in Q4 2020 was IFP Advisors, an estimated $10K added.
Based on aggregated 13F filings for Q4 2020.